Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health:In patients with type 2 diabetes (T2D) not achieving glycemic targets, ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Euronext to launch voluntary share exchange offer for all ATHEX shares Euronext announces the submission of a voluntary share ...

Overall, the quality factors provided an average annual performance boost for large stocks of about 1.1 percentage points and ...